141 related articles for article (PubMed ID: 28488190)
1. Computational dissection of allosteric inhibition of the SH2 domain of Bcr-Abl kinase by the monobody inhibitor AS25.
Ji M; Zheng G; Li X; Zhang Z; Jv G; Wang X; Wang J
J Mol Model; 2017 Jun; 23(6):183. PubMed ID: 28488190
[TBL] [Abstract][Full Text] [Related]
2. Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface.
Wojcik J; Lamontanara AJ; Grabe G; Koide A; Akin L; Gerig B; Hantschel O; Koide S
J Biol Chem; 2016 Apr; 291(16):8836-47. PubMed ID: 26912659
[TBL] [Abstract][Full Text] [Related]
3. How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study.
Zhang H; He X; Ni D; Mou L; Chen X; Lu S
J Biomol Struct Dyn; 2020 Jan; 38(1):89-100. PubMed ID: 30661457
[TBL] [Abstract][Full Text] [Related]
4. Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains.
Sha F; Gencer EB; Georgeon S; Koide A; Yasui N; Koide S; Hantschel O
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):14924-9. PubMed ID: 23980151
[TBL] [Abstract][Full Text] [Related]
5. Ensemble-based virtual screening: identification of a potential allosteric inhibitor of Bcr-Abl.
Singh VK; Coumar MS
J Mol Model; 2017 Jul; 23(7):218. PubMed ID: 28669127
[TBL] [Abstract][Full Text] [Related]
6. The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.
Ru Y; Wang Q; Liu X; Zhang M; Zhong D; Ye M; Li Y; Han H; Yao L; Li X
Sci Rep; 2016 Jun; 6():28352. PubMed ID: 27329306
[TBL] [Abstract][Full Text] [Related]
7. The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
Bai RY; Jahn T; Schrem S; Munzert G; Weidner KM; Wang JY; Duyster J
Oncogene; 1998 Aug; 17(8):941-8. PubMed ID: 9747873
[TBL] [Abstract][Full Text] [Related]
8. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL
Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701
[TBL] [Abstract][Full Text] [Related]
9. Targeting BCR tyrosine177 site with novel SH2-DED causes selective leukemia cell death in vitro and in vivo.
Peng Z; Yuan Y; Li YJ; Wang HX; Shi J; Cao WX; Luo HW; Deng JR; Feng WL
Int J Biochem Cell Biol; 2012 Jun; 44(6):861-8. PubMed ID: 22349215
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.
Hawk N; Sun T; Xie S; Wang Y; Wu Y; Liu J; Arlinghaus RB
Cancer Res; 2002 Jan; 62(2):386-90. PubMed ID: 11809685
[TBL] [Abstract][Full Text] [Related]
11. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
12. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.
Meyn MA; Wilson MB; Abdi FA; Fahey N; Schiavone AP; Wu J; Hochrein JM; Engen JR; Smithgall TE
J Biol Chem; 2006 Oct; 281(41):30907-16. PubMed ID: 16912036
[TBL] [Abstract][Full Text] [Related]
13. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
Singh VK; Chang HH; Kuo CC; Shiao HY; Hsieh HP; Coumar MS
J Biomol Struct Dyn; 2017 Jun; 35(8):1833-1848. PubMed ID: 27353341
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study.
Banavath HN; Sharma OP; Kumar MS; Baskaran R
Sci Rep; 2014 Nov; 4():6948. PubMed ID: 25382104
[TBL] [Abstract][Full Text] [Related]
15. The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
Zhang X; Wong R; Hao SX; Pear WS; Ren R
Blood; 2001 Jan; 97(1):277-87. PubMed ID: 11133772
[TBL] [Abstract][Full Text] [Related]
16. Evolution of BCR/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor.
Vaidya S; Vundinti BR; Shanmukhaiah C; Chakrabarti P; Ghosh K
PLoS One; 2015; 10(1):e0114828. PubMed ID: 25629972
[TBL] [Abstract][Full Text] [Related]
17. Insight into the allosteric inhibition of Abl kinase.
Fallacara AL; Tintori C; Radi M; Schenone S; Botta M
J Chem Inf Model; 2014 May; 54(5):1325-38. PubMed ID: 24787133
[TBL] [Abstract][Full Text] [Related]
18. SH2 Domain-Based FRET Biosensor for Measuring BCR-ABL Activity in Living CML Cells.
Fujioka M; Asano Y; Nakada S; Ohba Y
Methods Mol Biol; 2017; 1555():513-534. PubMed ID: 28092053
[TBL] [Abstract][Full Text] [Related]
19. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
Nieborowska-Skorska M; Slupianek A; Skorski T
Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572
[TBL] [Abstract][Full Text] [Related]
20. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
